Search Results - "Mendila, Myriam" :: K.UTB vyhledávací portál | TBU Library Retrieval Portal

Minimal Residual Disease Quantification Is an Independent Predictor of Progression-Free and Overall Survival in Chronic Lymphocytic Leukemia: A Multivariate Analysis From the Randomized GCLLSG CLL8 Trial

Minimal Residual Disease Quantification Is an Independent Predictor of Progression-Free and Overall Survival in Chronic Lymphocytic Leukemia: A Multivariate Analysis From the Randomized GCLLSG CLL8 Trial

by BÖTTCHER, Sebastian, RITGEN, Matthias, MENDILA, Myriam, WENDTNER, Clemens-Martin, EICHHORST, Barbara F, DÖHNER, Hartmut, HALLEK, Michael J, KNEBA, Michael, FISCHER, Kirsten, STILGENBAUER, Stephan, BUSCH, Raymonde M, FINGERLE-ROWSON, Günter, FINK, Anna Maria, BÜHLER, Andreas, ZENZ, Thorsten, WENGER, Michael Karl
Published in Journal of clinical oncology (20.03.2012)

Get full text

Journal Article

Rituximab Plus Fludarabine and Cyclophosphamide Prolongs Progression-Free Survival Compared With Fludarabine and Cyclophosphamide Alone in Previously Treated Chronic Lymphocytic Leukemia

Rituximab Plus Fludarabine and Cyclophosphamide Prolongs Progression-Free Survival Compared With Fludarabine and Cyclophosphamide Alone in Previously Treated Chronic Lymphocytic Leukemia

by Robak, Tadeusz, Dmoszynska, Anna, Solal-Céligny, Philippe, Warzocha, Krzysztof, Loscertales, Javier, Catalano, John, Afanasiev, Boris V, Larratt, Loree, Geisler, Christian H, Montillo, Marco, Zyuzgin, Ilya, Ganly, Peter S, Dartigeas, Caroline, Rosta, András, Maurer, Jörg, Mendila, Myriam, Saville, M Wayne, Valente, Nancy, Wenger, Michael K, Moiseev, Sergey I
Published in Journal of clinical oncology (01.04.2010)

Get full text

Journal Article

Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial

Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial

by Salles, Gilles, Prof, Seymour, John Francis, Prof, Offner, Fritz, Prof, López-Guillermo, Armando, MD, Belada, David, MD, Xerri, Luc, Prof, Feugier, Pierre, Prof, Bouabdallah, Réda, MD, Catalano, John Vincent, FRACP, Brice, Pauline, MD, Caballero, Dolores, MD, Haioun, Corinne, Prof, Pedersen, Lars Moller, MD, Delmer, Alain, Prof, Simpson, David, FRACP, Leppa, Sirpa, MD, Soubeyran, Pierre, Prof, Hagenbeek, Anton, Prof, Casasnovas, Olivier, MD, Intragumtornchai, Tanin, Prof, Fermé, Christophe, MD, da Silva, Maria Gomes, MD, Sebban, Catherine, MD, Lister, Andrew, Prof, Estell, Jane A, FRACP, Milone, Gustavo, MD, Sonet, Anne, MD, Mendila, Myriam, MD, Coiffier, Bertrand, Prof, Tilly, Hervé, Prof
Published in The Lancet (British edition) (2011)

Get full text

Journal Article

CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group

CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group

by Pfreundschuh, Michael, Trümper, Lorenz, Österborg, Anders, Pettengell, Ruth, Trneny, Marek, Imrie, Kevin, Ma, David, Gill, Devinder, Walewski, Jan, Zinzani, Pier-Luigi, Stahel, Rolf, Kvaloy, Stein, Shpilberg, Ofer, Jaeger, Ulrich, Hansen, Mads, Lehtinen, Tuula, López-Guillermo, Armando, Corrado, Claudia, Scheliga, Adriana, Milpied, Noel, Mendila, Myriam, Rashford, Michelle, Kuhnt, Evelyn, Loeffler, Markus
Published in The lancet oncology (01.05.2006)

Get full text

Journal Article

Prediction of Poor Outcome in CLL Patients Treated with FCR (Fludarabine, Cyclophosphamide, Rituximab) in the CLL8 Trial of the German CLL Study Group (GCLLSG)

Prediction of Poor Outcome in CLL Patients Treated with FCR (Fludarabine, Cyclophosphamide, Rituximab) in the CLL8 Trial of the German CLL Study Group (GCLLSG)

by Fink, Anna, Busch, Raymonde, Pflug, Natali, Boettcher, Sebastian, Winkler, Dirk, Buehler, Andreas, Ritgen, Matthias, Fischer, Kirsten, Eichhorst, Barbara, Wendtner, Clemens-Martin, Mendila, Myriam, Wenger, Michael K., Doehner, Hartmut, Kneba, Michael, Stilgenbauer, Stephan, Hallek, Michael
Published in Blood (18.11.2011)

Get full text

Journal Article

Minimal Residual Disease (MRD) Re-Growth Kinetics Are An Independent Predictor for Progression Free Survival (PFS) in Chronic Lymphocytic Leukemia (CLL) and Are Related to Biologically Defined CLL-Subgroups– Results From the CLL8 Trial of the German CLL Study Group (GCLLSG)

Minimal Residual Disease (MRD) Re-Growth Kinetics Are An Independent Predictor for Progression Free Survival (PFS) in Chronic Lymphocytic Leukemia (CLL) and Are Related to Biologically Defined CLL-Subgroups– Results From the CLL8 Trial of the German CLL Study Group (GCLLSG)

by Boettcher, Sebastian, Ritgen, Matthias, Fischer, Kirsten, Stilgenbauer, Stephan, Busch, Raymonde, Fingerle-Rowson, Gunter R., Fink, Anna-Maria, Buehler, Andreas, Winkler, Dirk, Wenger, Michael K., Mendila, Myriam, Wendtner, Clemens, Eichhorst, Barbara, Döhner, Hartmut, Hallek, Michael, Kneba, Michael
Published in Blood (18.11.2011)

Get full text

Journal Article

Gene Mutations and Treatment Outcome in Chronic Lymphocytic Leukemia: Results From the CLL8 Trial

Gene Mutations and Treatment Outcome in Chronic Lymphocytic Leukemia: Results From the CLL8 Trial

by Stilgenbauer, Stephan, Busch, Raymonde, Schnaiter, Andrea, Paschka, Peter, Rossi, Marianna, Döhner, Konstanze, Zenz, Thorsten, Bühler, Andreas, Winkler, Dirk, Edelmann, Jennifer, Mertens, Daniel, Bullinger, Lars, Kless, Sabrina, Mack, Silja, Böttcher, Sebastian, Ritgen, Matthias, Kneba, Michael, Jäger, Ulrich, Lichter, Peter, Patten, Nancy, Wenger, Michael K., Mendila, Myriam, Fingerle-Rowson, Gunter, Cazzola, Mario, Wendtner, Clemens, Fink, Anna Maria, Fischer, Kirsten, Hallek, Michael, Döhner, Hartmut
Published in Blood (16.11.2012)

Get full text

Journal Article

Serum Factors Predict Therapeutic Outcome In Patients with Chronic Lymphocytic Leukemia Treated In the CLL8 Trial of the German CLL Study Group (GCLLSG)

Serum Factors Predict Therapeutic Outcome In Patients with Chronic Lymphocytic Leukemia Treated In the CLL8 Trial of the German CLL Study Group (GCLLSG)

by Fink, Anna, Pflug, Natali, Busch, Raymonde, Fingerle-Rowson, Gunter R., Eichhorst, Barbara, Wendtner, Clemens-Martin, Winkler, Dirk, Buehler, Andreas, Mendila, Myriam, Wenger, Michael, Dohner, Hartmut, Stilgenbauer, Stephan, Hallek, Michael, Fischer, Kirsten
Published in Blood (19.11.2010)

Get full text

Journal Article

TP53 Mutations and Outcome After Fludarabine and Cyclophosphamide (FC) or FC Plus Rituximab (FCR) in the CLL8 Trial of the GCLLSG

TP53 Mutations and Outcome After Fludarabine and Cyclophosphamide (FC) or FC Plus Rituximab (FCR) in the CLL8 Trial of the GCLLSG

by Zenz, Thorsten, Hoth, Patrick, Busch, Raymonde, Helfrich, Hanne, Winkler, Dirk, Bühler, Andreas, Patten, Nancy, Truong, Sim, Wu, Lin, Fingerle-Rowson, Günther, Fischer, Kirsten, Fink, Anna-Maria, Jäger, Ulrich, Böttcher, Sebastian, Kneba, Michael, Wenger, Michael K., Mendila, Myriam, Hallek, Michael, Döhner, Hartmut, Stilgenbauer, Stephan
Published in Blood (20.11.2009)

Get full text

Journal Article

First-Line Treatment with Fludarabine (F), Cyclophosphamide (C), and Rituximab (R) (FCR) Improves Overall Survival (OS) in Previously Untreated Patients (pts) with Advanced Chronic Lymphocytic Leukemia (CLL): Results of a Randomized Phase III Trial On Behalf of An International Group of Investigators and the German CLL Study Group

First-Line Treatment with Fludarabine (F), Cyclophosphamide (C), and Rituximab (R) (FCR) Improves Overall Survival (OS) in Previously Untreated Patients (pts) with Advanced Chronic Lymphocytic Leukemia (CLL): Results of a Randomized Phase III Trial On Behalf of An International Group of Investigators and the German CLL Study Group

by Hallek, Michael, Fingerle-Rowson, Guenter, Fink, Anna-Maria, Busch, Raymonde, Mayer, Jiri, Hensel, Manfred, Hopfinger, Georg, Hess, Georg, von Gruenhagen, Ulrich, Bergmann, Manuela A., Catalano, John, Zinzano, Pier Luigi, Cappio, Federico Caligaris, Seymour, John F, Berrebi, Alain, Jaeger, Ulrich, Cazin, Bruno, Trneny, Marek, Westermann, Anne, Wendtner, Clemens-Martin, Eichhorst, Barbara F., Staib, Peter, Boettcher, Sebastian, Ritgen, Matthias, Mendila, Myriam, Kneba, Michael, Doehner, Hartmut, Stilgenbauer, Stephan, Fischer, Kirsten
Published in Blood (20.11.2009)

Get full text

Journal Article

4.19 Prediction of Poor Outcome in Chronic Lymphocytic Leukemia Patients treated with FCR (Fludarabine, Cyclophosphamide, Rituximab) in the CLL8 Trial of the German CLL Study Group

4.19 Prediction of Poor Outcome in Chronic Lymphocytic Leukemia Patients treated with FCR (Fludarabine, Cyclophosphamide, Rituximab) in the CLL8 Trial of the German CLL Study Group

by Fink, Anna, Busch, Raymonde, Pflug, Natali, Boettcher, Sebastian, Winkler, Dirk, Buehler, Andreas, Ritgen, Matthias, Fischer, Kirsten, Eichhorst, Barbara, Wendtner, Clemens-Martin, Mendila, Myriam, Wenger, Michael K, Doehner, Hartmut, Kneba, Michael, Stilgenbauer, Stephan, Hallek, Michael
Published in Clinical lymphoma, myeloma and leukemia (01.10.2011)

Get full text

Journal Article

Genomic Aberrations, VH Mutation Status and Outcome after Fludarabine and Cyclophosphamide (FC) or FC Plus Rituximab (FCR) in the CLL8 Trial

Genomic Aberrations, VH Mutation Status and Outcome after Fludarabine and Cyclophosphamide (FC) or FC Plus Rituximab (FCR) in the CLL8 Trial

by Stilgenbauer, Stephan, Zenz, Thorsten, Winkler, Dirk, Bühler, Andreas, Busch, Raymonde, Fingerle-Rowson, Günther, Fischer, Kirsten, Fink, Anna- Maria, Jäger, Ulrich, Böttcher, Sebastian, Kneba, Michael, Wenger, Michael, Mendila, Myriam, Hallek, Michael, Döhner, Hartmut
Published in Blood (16.11.2008)

Get full text

Journal Article

$Rituximab, Fludarabine, and Cyclophosphamide (R-FC) Prolongs Progression Free Survival in Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) Compared with FC Alone: Final Results from the International Randomized Phase III REACH Trial$

Rituximab, Fludarabine, and Cyclophosphamide (R-FC) Prolongs Progression Free Survival in Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) Compared with FC Alone: Final Results from the International Randomized Phase III REACH Trial

by Robak, Tadeusz, Moiseev, Sergey I, Dmoszynska, Anna, Solal-Céligny, Philippe, Warzocha, Krzysztof, Loscertales, Javier, Catalano, John, Afanasiev, Boris V, Larratt, Loree, Geisler, Christian, Montillo, Marco, Ganly, Peter, Dartigeas, Caroline, Rosta, András, Janssens, Ann, Mendila, Myriam, Maurer, Jörg, Wenger, Michael K.
Published in Blood (16.11.2008)

Get full text

Journal Article

Immunochemotherapy with Fludarabine (F), Cyclophosphamide (C), and Rituximab (R) (FCR) Versus Fludarabine and Cyclophosphamide (FC) Improves Response Rates and Progression-Free Survival (PFS) of Previously Untreated Patients (pts) with Advanced Chronic Lymphocytic Leukemia (CLL)

Immunochemotherapy with Fludarabine (F), Cyclophosphamide (C), and Rituximab (R) (FCR) Versus Fludarabine and Cyclophosphamide (FC) Improves Response Rates and Progression-Free Survival (PFS) of Previously Untreated Patients (pts) with Advanced Chronic Lymphocytic Leukemia (CLL)

by Hallek, Michael, Fingerle-Rowson, Guenter, Fink, Anna- Maria, Busch, Raymonde, Mayer, Jiri, Hensel, Manfred, Hopfinger, Georg, Hess, Georg, von Gruenhagen, Ulrich, Bergmann, Manuela A., Catalano, John, Zinzani, Pier Luigi, Cappio, Federico Caligaris, Seymour, John Francis, Berrebi, Alain, Jaeger, Ulrich, Cazin, Bruno, Trneny, Marek, Westermann, Anne, Wendtner, Clemens-Martin, Eichhorst, Barbara F., Staib, Peter, Boettcher, Sebastian, Ritgen, Matthias, Stilgenbauer, Stephan, Mendila, Myriam, Kneba, Michael, Döhner, Hartmut, Fischer, Kirsten
Published in Blood (16.11.2008)

Get full text

Journal Article

$Interim Results of a Phase I/II Study of Ocrelizumab, a New Humanised Anti-CD20 Antibody in Patients with Relapsed/Refractory Follicular Non-Hodgkin's Lymphoma$

Interim Results of a Phase I/II Study of Ocrelizumab, a New Humanised Anti-CD20 Antibody in Patients with Relapsed/Refractory Follicular Non-Hodgkin's Lymphoma

by Morschhauser, Franck, Marlton, Paula, Vitolo, Umberto, Linden, Ola, Seymour, John, Crump, Michael, Coiffier, Bertrand, Pulsoni, Alessandro, Belch, Andrew, Lerch, Erika, Kimby, Eva, Arnljots, Kristina, Wassner, Elisabeth, Mendila, Myriam
Published in BLOOD (16.11.2007)

Get full text

Journal Article Conference Proceeding

Normalization of cytomegalovirus-specific CD4 T cells in HIV-1-infected individuals receiving antiretroviral therapy

Normalization of cytomegalovirus-specific CD4 T cells in HIV-1-infected individuals receiving antiretroviral therapy

by GROSSE, Volker, SCHULTE, Alexander, WEBER, Klaus, MENDILA, Myriam, JACOBS, Roland, SCHMIDT, Reinhold E, HEIKEN, Hans
Published in AIDS (London) (03.05.2002)

Get full text

Journal Article

Highly active antiretroviral therapy

Highly active antiretroviral therapy

by Behrens, Georg, Knuth, Christine, Schedel, Ingolf, Mendila, Myriam, Schmidt, Reinhold E
Published in The Lancet (British edition) (04.04.1998)

Get full text

Journal Article

Progressive Reduction of CMV-Specific CD4 + T Cells in HIV-1 Infected Individuals During Antiretroviral Therapy

Progressive Reduction of CMV-Specific CD4 + T Cells in HIV-1 Infected Individuals During Antiretroviral Therapy

by Grosse, Volker, Schulte, Alexander, Weber, Klaus, Mendila, Myriam, Jacobs, Roland, Schmidt, Reinhold E., Heiken, Hans
Published in Immunobiology (1979) (01.08.2000)

Get full text

Journal Article